Breast Cancer Clinical Trial

The Young Women’s Breast Cancer Study

Summary

The investigators are conducting a longitudinal cohort study of young women with breast cancer. The investigators identify women age 40 and younger with newly-diagnosed breast cancer from academic and community healthcare institutions. After women consent to the study, they fill-out surveys and give blood samples, and the investigators collect tissue from their breast cancer tumor after it is removed. Women are surveyed every 6 months for the first 3 years after diagnosis, then yearly thereafter for an additional 7 years (for a total follow-up of at least 10 years following diagnosis). The study investigates short and long-term disease and treatment issues, tumor biology and the relationship to patient outcomes, and psychosocial concerns at baseline and in follow-up among a cohort of young women who are newly-diagnosed with breast cancer.

View Full Description

Full Description

This is a longitudinal cohort study of young women with breast cancer. Over a 6-year period, the investigators aim to identify over 1,600 women age 40 and younger with newly diagnosed breast cancer from academic and community health care institutions. It is anticipated that 1,300 of these women will agree to participate in an observational study. Patient surveys, medical record review, and blood and tissue collection will be utilized. Women will be surveyed every 6 months for the first 3 years after diagnosis, then yearly thereafter for an additional 7 years (for a total follow-up of 10 year following diagnosis). The study will investigate short and long-term disease and treatment issues, and psychosocial concerns at baseline and in follow-up among a cohort of young women (age 40 or younger) newly diagnosed with breast cancer. The investigators aim to characterize the population of young women at diagnosis and in follow-up regarding disease and psychosocial outcomes (e.g., presentation and disease characteristics, treatment patterns and quality of care, short and long-term side effects, and psychosocial concerns including fertility, sexual functioning, and menopausal issues). The investigators will also collect tumor and blood specimens to characterize the tumors, and bank for future studies including molecular evaluations of disease characteristics, genetic variability and hormonal levels in blood. Ultimately, the investigators aim to develop predictors of outcome, and identify areas that may be amenable to intervention.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Female
Diagnosis of breast cancer
Age 40 or younger at diagnosis
Informed consent obtained from patient
Ability to understand written and spoken English to the extent necessary to complete the questionnaires

Exclusion Criteria:

Inability to understand written and spoken English to the extent necessary to complete the questionnaires
Absence of informed consent

Study is for people with:

Breast Cancer

Estimated Enrollment:

1302

Study ID:

NCT01468246

Recruitment Status:

Active, not recruiting

Sponsor:

Dana-Farber Cancer Institute

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 11 Locations for this study

See Locations Near You

University of Colorado Cancer Center
Aurora Colorado, 80045, United States
Beth-Israel Deaconess Medical Center
Boston Massachusetts, 02215, United States
Dana-Farber Cancer Institute
Boston Massachusetts, 02215, United States
Massachusetts General Hospital
Boston Massachusetts, 02215, United States
MGH/North Shore Cancer Center
Danvers Massachusetts, 01923, United States
Cape Cod Hospital
Hyannis Massachusetts, 02601, United States
Lowell General Hospital
Lowell Massachusetts, 01854, United States
DF/BWCC at Milford Regional Medical Center
Milford Massachusetts, 01757, United States
Newton-Wellesley Hospital
Newton Massachusetts, 02462, United States
South Shore Hospital
South Weymouth Massachusetts, 02190, United States
Mayo Clinic
Rochester Minnesota, 55905, United States
Dana-Farber/New Hampshire Oncology-Hematology
Londonderry New Hampshire, 03053, United States
Sunnybrook Health Sciences Centre
Toronto Ontario, 3M5, Canada

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Estimated Enrollment:

1302

Study ID:

NCT01468246

Recruitment Status:

Active, not recruiting

Sponsor:


Dana-Farber Cancer Institute

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.